ARK kidney
A normothermic perfusion for ex vivo kidney preservation
CAUTION -- Investigational device. Limited by Federal (or United States) law to investigational use
WATCH THE SYSTEM
Status of development
Kidney and liver preclinical studies with a pig model have been finished and the final version of the ARK device is already available for mass manufacturing. The company holds an ISO13485 certification and expects to obtain the CE mark of the ARK system for kidney preservation in Q1 2021. Product launch is planned for the first half of 2021. The CE mark of the ARK system for liver preservation is expected for 2021 and will be followed by another pivotal study for liver transplantation. Product launch of the liver preservation version is planned for 2022.
History
EBERS was founded in 2009 by a group of members of the University of Zaragoza led by Pedro Moreo (LinkedIn) and Víctor Alastrué (LinkedIn), who left the academic world to start the business. Still today Pedro and Víctor run the company as CEO and CTO, respectively.
In the beginning, EBERS was focused on the design and fabrication of advanced laboratory equipment for cell culture, with a special emphasis on tissue and organ engineering and 3D cell culture applications. This continues being an active business line of the company, with cell culture products being sold to academic and research customers all over the world and new products being launched frequently.
In 2014 EBERS decided to expand its business by entering the medical device market with a new technology for ex vivo organ preservation. This decision was motivated in first place by the demands of transplant surgeons for better systems for organ preservation. Also, the management team of the company was convinced that the know-how and experience acquired by EBERS in the field of tissue and organ regeneration would be valuable to develop excellent products for organ preservation.
This website is exclusively dedicated to the business line of EBERS dealing with medical technology for organ preservation. If you are interested in our cell culture products, we encourage you to visit our alternative site, where you will find updated detailed information on the rest of our product lines.
News
- “Cutting-edge Regenerative Medicine” symposium
- Training and demonstration session in Hospital Clínic in Barcelona
- EBERS at the ESOT 2021 congress in Milan
- Oral presentation in the Clinical Sessions of the Clinical Hospital of Barcelona
- Participation in The Transplantation Society 28thInternational Congress (TTS 2020)
Press center
- Este es el innovador invento aragonés que permitirá duplicar el número de órganos útiles para trasplantar
- Más de 1.000 proyectos españoles de innovación despegan con el apoyo de la Comisión Europea
- Tres pymes españolas cuentan cómo han hecho realidad sus proyectos de innovación gracias a la Comisión Europea
- Historias de pymes capaces de cambiar la vida de las personas y hacer rentables sus negocios
- Una start-up aragonesa cambia las reglas del trasplate de órganos con apoyo europeo
R&D Projects
The following research and developement projects have supported the developement of the ARK system.
| # | Acronym |
|---|---|
| 1 | PRENOMON |
| 2 | PREDICTOR |
| 3 | NORMOPERF - Phase I |
| 4 | NORMOPERF - Phase II |
Contact Us
EBERS Medical Technology SL
Polígono Malpica. Calle F Oeste
Grupo Gregorio Quejido, nave 63.
50016 Zaragoza (España)
Tel. & Fax: (+34) 876 013 826